Copyright Nasdaq. Minimum 15 minutes delayed.

Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dicerna to Present at Jefferies 2017 Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will present at the Jefferies 2017...
View HTML
Toggle Summary Dicerna Reports First Quarter 2017 Financial and Operational Results and Provides Corporate Update
Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operational results for the first quarter...
View HTML
Toggle Summary Dicerna to Report First Quarter 2017 Financial Results and Host Conference Call on May 8, 2017
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2017 financial results after market close on Monday, May 8,...
View HTML
Toggle Summary Dicerna Announces Closing of $70 Million Convertible Preferred Stock Financing
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company"), a leading developer of investigational ribonucleic acid interference ("RNAi") therapeutics, today announced that it has closed its previously announced stock purchase transaction for the sale of...
View HTML
Toggle Summary Dicerna Reports Fourth Quarter and Full Year 2016 Financial and Operational Results
Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operational results for the fourth...
View HTML
Toggle Summary Dicerna Secures $70 Million in Convertible Preferred Stock Financing
Provides Sufficient Cash into 2019 CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that it has signed a stock purchase agreement with a...
View HTML
Toggle Summary Dicerna Pharmaceuticals to Present at the BioCentury 24th Annual Future Leaders in the Biotech Industry Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will present a corporate update at...
View HTML
Toggle Summary Dicerna to Report Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call on March 30, 2017
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its fourth quarter and full year 2016 financial results after market close on...
View HTML
Toggle Summary Dicerna to Present at Cowen and Company 37th Annual Health Care Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will present at the Cowen and Company...
View HTML
Toggle Summary Dicerna to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will participate in an analyst-led fireside chat...
View HTML